Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX 株式レポート

時価総額:US$358.8m

Amylyx Pharmaceuticals 将来の成長

Future 基準チェック /06

Amylyx Pharmaceuticalsの収益は年間68.6%で減少すると予測されていますが、年間利益は年間36.5%で増加すると予想されています。EPS は年間33.3%で増加すると予想されています。

主要情報

36.5%

収益成長率

33.3%

EPS成長率

Pharmaceuticals 収益成長23.9%
収益成長率-68.6%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日18 Nov 2024

今後の成長に関する最新情報

Recent updates

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 25

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10
Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16
This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16
Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

業績と収益の成長予測

NasdaqGS:AMLX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20260-84N/AN/A5
12/31/2025N/A-105N/AN/A6
12/31/202488-298N/AN/A5
9/30/2024196-259-132-95N/A
6/30/2024299-166-60-59N/A
3/31/2024398-711517N/A
12/31/2023381491112N/A
9/30/20232942-53-51N/A
6/30/2023192-73-91-89N/A
3/31/202394-149-147-144N/A
12/31/202222-198-182-180N/A
9/30/20220-184-161-158N/A
6/30/20220-153-138-136N/A
3/31/20220-121-103-103N/A
12/31/20210-88-75-75N/A
9/30/20211-68-56-55N/A
12/31/20201-42-37-37N/A
12/31/20191-14-11-11N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AMLX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AMLXの収益は今後 3 年間で減少すると予想されています (年間-68.6% )。

高い収益成長: AMLXの収益は今後 3 年間で減少すると予測されています (年間-68.6% )。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: AMLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘